secwatch.observer — SEC 8-K summary
======================================

Issuer:     AXIM BIOTECHNOLOGIES, INC. (AXIM)
CIK:        0001514946
Form:       8-K
Filed at:   2022-03-09T23:59:59+00:00
Accession:  0001096906-22-000524
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AXIM shifts COVID-19 NAb test to RUO; separates from Empowered Diagnostics
--------------------------------------------------------------------------

- COVID-19 NAb test now offered For Research Use Only after FDA changed priorities from qualitative testing.
- Entered separation agreement with Empowered Diagnostics, LLC following FDA recall of their products.
- Two RUO tests available: quantitative (exact number) and semi-quantitative (high/medium/low titers).
- Partner Dr. Lake conducting ongoing correlative study at ASU on vaccine vs natural immunity NAb levels.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1514946/000109690622000524/0001096906-22-000524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1514946/000109690622000524/axim-20220307.htm
  HTML page:      https://secwatch.observer/filing/0001096906-22-000524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer